FDA in 2020: What a Year! (Part 2 of 3)
By EsqSocial Corporation 22/12/20
Following up on our colleagues’ post earlier this month covering the Food and Drug Administration’s 2020 device law and policy activities, this post will explore prescription drug and biologic law and policy developments over the past year. We’ll also begin looking forward into 2021 and the agency’s transition to an incoming Biden Administration. One of the highest priorities for the Food and Drug Administration (FDA) during this “pandemic year 1” was authorizing the use of COVID-19 medical...
By: Mintz - Health Care Viewpoints